Few data about the impact of emotional distress (ED) on treatment efficacy in patients with metastatic breast cancer (mBC) are available.
Aim of this study is to assess the outcomes of patients with mBC receiving first-line treatment according to the presence of baseline ED.
Age over 18 years
Confirmed histological diagnosis of breast cancer
No prior treatment for advanced/metastatic cancer
cohort A (HR-/HER2-, PD-L1+): pembrolizumab or atezolizumab + chemotherapy
Pre-existing severe psychiatric disorders or other conditions that could impair the ability to provide informed consent
Inability to complete questionnaires
Presence of another malignancy in the previous 3 years
Symptomatic brain metastases
European Institute of Oncology
Lead sponsor